Published November 2018 | Version v1
Journal article Metadata-only

Lymphoblastic Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group (ILROG)

Creators

  • 1. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston (United States)
  • 2. Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen (Denmark)
  • 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York (United States)

Description

Presentation with a large mediastinal mass is a hallmark of acute lymphoblastic lymphoma, a disease that is treated in the same way as acute lymphoblastic leukemia even in the absence of marrow involvement. The role of mediastinal radiation for patients who achieve complete remission after chemotherapy has been overlooked and controversial. This document presents current knowledge on the role of radiation for lymphoblastic lymphoma and best practices for addressing how to deliver mediastinal radiation with modern technology.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2018.05.078

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2018.05.078;
PII
S0360301618309313;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
102
Journal Issue
3
Journal Page Range
p. 508-514
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
54107131
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CHEMOTHERAPY; LEUKEMIA; LYMPHOMAS; PATIENTS; RECOMMENDATIONS
Descriptors DEC
DISEASES; IMMUNE SYSTEM DISEASES; MEDICINE; NEOPLASMS; THERAPY

Optional Information

Copyright
Copyright (c) 2018 Elsevier Inc. All rights reserved.